CGM initiation within 1st year of diagnosis proven to reduce A1C

Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study

Anagha Champakanath, Halis Kaan Akturk, G. Todd Alonso, Janet K. Snell-Bergeon, and Viral N. Shah Diabetes Care. 2022 Mar 1;45(3):750-753. doi: 10.2337/dc21-2004.

This is an extension of a previously published study. Electronic medical records of patients with type 1 diabetes (T1D) were evaluated, between 1 and 35 years of age, diagnosed between January 2013 and December 2015. For the extension study, data were collected at each visit from the onset of T1D through a 7-year follow-up period.¹

Objective

The purpose of this study was to evaluate improving A1C levels and the long-term glycemic outcomes of CGM initiation within the first year of type 1 diabetes diagnosis.

Study Outcomes Measured

The primary outcome of the study was the change in A1C over time between the CGM and non-CGM groups, monitoring improving A1C levels in patients

The secondary outcome was the difference in A1C between the new CGM group* and non-CGM group

shaw 7 year study improving A1C levels in Type 1 diabetes patients

Results

A total of 396 people with T1D (n=372 children aged < 18 years; n=24 adults aged ≥ 18 years) were included in the analysis and followed up to 7 years. A1C was significantly lower in the ongoing CGM group compared to the no-CGM group throughout the 7-year follow up period, adjusting for age at diagnosis, sex, and insulin delivery method followed for 7 years.¹

^{Key TAKEAWAYS}

CGM initiation within the first year of T1D diagnosis resulted in long-term improvements in A1C¹

First study¹ to demonstrate improvement in A1C over 7 years with CGM initiation within first year of diabetes diagnosis in patients with T1D. However, improvements in A1C were seen with use of CGM regardless of when it was initiated.

Sustained improvement in A1C was significantly better in those who initiated CGM within the first year of diabetes diagnosis compared with CGM initiation after 2.5 years of T1D. While the general target A1C average for adults with diabetes is below 7%, individual goals vary based on factors like patient age, health conditions, and risk of hypoglycemia.

1. Anagha Champakanath, Halis Kaan Akturk, G. Todd Alonso, Janet K. Snell-Bergeon, Viral N. Shah; Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study; Diabetes Care 2022 Mar 1;45(3):750-753. doi: 10.2337/dc21-2004.

LBL-1002664 Rev001

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Request a Visit from a Dexcom Representative

Request a G7 Sample

Request Stelo Education Materials

Request Stelo Wholesale Order Purchase Info

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Do not include prefix (Mr., Mrs., Dr.)

As listed on Provider’s medical license (no MD, Jr., Sr.)

Please use the Provider’s NPI

Please provide Facility/Office address Only- We will not ship to home address

Is your patient on a connected pump device?

Yes

By submitting the above form, I certify that I am a licensed practitioner, authorized to receive and dispense samples of the Dexcom G6 Continuous Glucose Monitoring System and/or Dexcom‘s next generation product, Dexcom G7 (the "Samples"). I represent that I am requesting the Samples for evaluation purposes and that I will not (i) sell, resell, barter, return for credit or seek reimbursement for the use of the Samples, or (ii) for professional services for dispensing or evaluating the Samples, I also agree to inform my patients that they should not submit claims for reimbursement to any third party for any Samples.

The Samples are FDA cleared for use with a compatible smart device or separate piece of durable medical equipment called a receiver. Neither devices nor receivers are included in the Samples. Accordingly, and in light of the applicable G6 or G7 Dexcom Instructions for Use, you should dispense Samples only to a patient who (or whose authorized caregiver), in the exercise of your clinical judgment, (i) has reliable access to a compatible smart device and/or automated insulin delivery system, and (ii) is capable of safely using the Samples with their smart device, without the need for a separate dedicated receiver.

Please note that Medicare will reimburse for sensors only if the beneficiary also uses a receiver covered by Medicare. Accordingly, it is appropriate to give Samples to Medicare patients only if they have (in the case of the G6 Samples) or would be eligible to obtain (in the case of the G7 Samples), a Medicare-covered receiver.

You agree that you will not provide the Samples to any patients that are beneficiaries under the Maine or Colorado state Medicaid programs. I understand that Dexcom will be tracking, and if necessary, reporting and may be subject to disclosure requirements with respect to the provision of these Samples. I agree not to reuse any Samples. I acknowledge that Dexcom provides no warranties for the Samples other than the warranties outlined in the applicable Dexcom Instructions for Use. I will comply with all applicable federal, state and local laws in receiving and dispensing these Samples, and I agree to store and use these Samples in a manner consistent with the applicable Dexcom Instructions for Use. Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. ©2023 Dexcom, Inc. All rights reserved.

LBL-1004145 Rev001

By submitting the above form, I certify that I am a licensed practitioner, authorized to receive and dispense these Dexcom G6 Continuous Glucose Monitoring Systems and/or Dexcom‘s next generation product, Dexcom G7 (the "Dexcom Education Devices") which are provided in the quantities listed above.

The Dexcom Education Devices are FDA cleared for use with a compatible smart device or separate piece of durable medical equipment called a receiver. Neither smart devices nor receivers are included with the Dexcom Education Devices. I understand that these Dexcom Education Devices are being requested for me and other healthcare professionals ("HCPs") for evaluation purposes to learn more about the Dexcom Education Devices and experience the benefits of the Dexcom Education Devices through a product demonstration, and that each HCP will need a compatible smart device for the product demonstration.

I acknowledge that Dexcom provides no warranties for the Dexcom Education Devices other than the warranties outlined in the applicable Dexcom Instructions for Use. I will comply with all applicable federal, state and local laws in receiving and dispensing these Dexcom Education Devices in a manner consistent with the applicable Dexcom Instructions for Use, and agree not to reuse any Dexcom Education Devices. I agree to receive, store, distribute, and/or use these Dexcom Education Devices in a manner consistent with the applicable Dexcom Instructions for Use and device labeling. I understand that Dexcom will be tracking, and if necessary, reporting and may be subject to disclosure requirements with respect to the provision of these Dexcom Education Devices. I understand and agree to properly dispose of the Dexcom Education Devices immediately following the completion of the product demonstration. The Dexcom Education Devices are being provided at no cost, without any expectation of remuneration, HCPs have no obligations under the federal supply schedule contract for participating in the product demonstration, and Dexcom waives any rights under this contract or applicable law to pursue a claim for the costs associated with the Dexcom Education Devices.

Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. ©2023 Dexcom, Inc. All rights reserved.

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.

CGM initiation within 1st year of diagnosis proven to reduce A1C

Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study

Key TAKEAWAYS

Related Content

Contact Us

^{Key TAKEAWAYS}